DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Lung fibrosis 10 years after cessation of bleomycin therapy.

File Description SizeFormat
Tohoku J.Exp.Med 216 1 77.pdf647.85 kBAdobe PDFView/Open

Title: Lung fibrosis 10 years after cessation of bleomycin therapy.
Authors: Tashiro, Masato / Izumikawa, Koichi / Yoshioka, Daisuke / Nakamura, Shigeki / Kurihara, Shintaro / Sakamoto, Noriho / Seki, Masafumi / Kakeya, Hiroshi / Yamamoto, Yoshihiro / Yanagihara, Katunori / Mukae, Hiroshi / Hayashi, Tomayoshi / Fukushima, Kiyoyasu / Tashiro, Takayoshi / Kohno, Shigeru
Issue Date: Sep-2008
Citation: The Tohoku Journal of Experimental Medicine 216(1), pp.77-80; 2008
Abstract: Bleomycin (BLM) is a chemotherapeutic agent used for the treatment of several types of malignancy, including germ cell tumors, lymphoma, and certain types of squamous-cell carcinoma. The common adverse effect of BLM is interstitial pneumonitis, followed by pulmonary fibrosis. BLM-induced pneumonitis occurs in up to 46% of patients treated with BLM-containing chemotherapy and lung toxicity usually appears during treatment. Here we describe a patient with lung fibrosis, who presented with slow progressive breathlessness and pneumothorax more than 10 years after cessation of BLM therapy. A 15 year-old girl presented with abnormal shadows on chest X-ray. The patient had a yolk sac carcinoma in the sacral region at 1 year of age and obtained complete remission after being treated with tumor resection, radiation, and several anti-cancer drugs including BLM. There were no abnormal findings in chest X-ray until she reached 3 years of age, when she had developed respiratory distress that worsened with age. The patient had experienced an episode of pneumothorax at 13 years of age. Chest CT at the time revealed interstitial reticular opacities. Radiological findings and pathological examination of the lung tissue obtained during bullectomy with video-assisted thoracic surgery were compatible with BLM-induced pneumonitis. The present study suggests that lung fibrosis may surface more than 10 years after cessation of BLM therapy at the age of 1 year, with no chest radiographic findings 1 year after completion of chemotherapy. The use of BLM in infants requires strict supervision and observation and careful long-term follow up.
Keywords: Bleomycin / Child / Pneumonitis / Pneumothorax
URI: http://hdl.handle.net/10069/20698
ISSN: 00408727
DOI: 10.1620/tjem.216.77
PubMed ID: 18719341
Rights: Copyright (c) 2008 TOHOKU UNIVERSITY MEDICAL PRESS. All rights reserved.
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/20698

All items in NAOSITE are protected by copyright, with all rights reserved.


Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace